January 27, 2020

**BSE Limited**
Department of Corporate Services,
P. J. Towers,
Dalal Street,
**MUMBAI - 400 001.**

**National Stock Exchange of India Limited**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
**Mumbai - 400 051.**

***Dear Sirs,***

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards successful completion of the inspection carried out by the UK Medicines and Healthcare products Regulatory Agency, the regulatory agency of the United Kingdom (UK) at the Company's three manufacturing units in Pithampur (India).

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

**For LUPIN LIMITED**

For **R. V. SATAM**
**COMPANY SECRETARY**
**(ACS - 11973)**

LUPIN LIMITED MUMBAI INDIA

**Encl.: a/a**

*Press Note*

| BSE: 500257 | NSE: LUPIN | REUTERS: LUPIN.BO | BLOOMBERG: LPC IN Equity |
|---|---|---|---|

# Lupin's Pithampur facilities complete successful MHRA inspection

**Mumbai, January 27, 2020**: Pharma major Lupin Limited (Lupin) today announced the successful completion of the inspection carried out by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory agency of the United Kingdom (UK) at its three manufacturing units in Pithampur (India).

The inspection for the three units at Pithampur closed with no critical observation and one major observation.

Commenting on the positive development, **Nilesh Gupta, Managing Director, Lupin** said, "We are pleased with the outcome of the inspection by the UK MHRA. It is a meaningful development for our Pithampur facilities. We uphold the highest quality standards across all our manufacturing sites and are committed to maintain global benchmarks."

**About Lupin Limited**

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8$^{th}$ largest generics pharmaceutical company by revenues (June 30, 2019, Bloomberg LTM). The Company is the 3$^{rd}$ largest pharmaceutical player in the US by prescriptions (IQVIA MAT September 2019); 3$^{rd}$ largest Indian pharmaceutical company by global revenues (June 30, 2019, Bloomberg LTM); and 6$^{th}$ largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2019).

For the financial year ended March 31, 2019, Lupin's Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on LinkedIn and Facebook at https://www.linkedin.com/company/lupinglobal/ and https://www.facebook.com/Lupin-Global respectively.

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055

**For further information or queries please contact:**

**Arvind Bothra**
Head – Investor Relations and M&A / Corporate Communications
Email: arvindbothra@lupin.com |
Ph: +91-22-66408237